ARCA Biopharma Inc — Company Overview, News & Financial Data
ARCA Biopharma develops genetically-targeted therapies for cardiovascular diseases, aiming to improve patient outcomes.
ARCA Biopharma Inc
Company profile
About ARCA Biopharma Inc
ARCA Biopharma (NASDAQ: ABIO) focuses on developing genetically-targeted therapies for cardiovascular diseases. They're working on innovative projects like Gencaro, aimed at treating atrial fibrillation in heart failure patients. Their objective is to harness precision medicine to improve patient outcomes, leveraging genetic insights to create more effective treatments. With a clear dedication to advancing cardiovascular health, ARCA is pushing the boundaries of biopharmaceutical innovation.
Snapshot
2004Year founded
3Employees
Westminster, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
Westminster, US
Products and/or services of ARCA Biopharma Inc
- Gencaro: A precision medicine program for developing targeted therapies to treat cardiovascular diseases, specifically heart failure and atrial fibrillation.
- Nuventra: Strategic partnership for clinical pharmacology and pharmacokinetic expertise to accelerate drug development.
- Ethics-First Approach: Prioritizing patient safety and rigorous ethical standards in all research and development initiatives.
- Adaptive Clinical Trial Design: Utilizing advanced clinical trial methodologies to optimize drug development processes and outcomes.
- Biomarker Development: Identifying and validating biomarkers to enhance the precision and efficacy of treatment modalities.
- Regulatory Expertise: Leveraging in-depth knowledge of regulatory pathways to expedite the approval and commercialization of innovative therapies.
ARCA Biopharma Inc executive team
- Mr. Thomas A. KeuerPresident, COO & Principal Executive Officer
- Mr. C. Jeffrey Dekker CPACFO, Treasurer & Company Secretary
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift